What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?

What does the pharmacoeconomic landscape currently look like for PCSK9 inhibition, especially in light of the recent price reductions for alirocumab and evolocumab?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Lipidologist and Atherosclerosis Specialist's Perspective

Presenter

Sergio Fazio, MD

Sergio Fazio, MD

Director, Center for Preventive Cardiology

Director, Center for Preventive Cardiology
Professor of Medicine
Division of Cardiovascular Medicine
School of Medicine
Oregon Health Sciences University (OHSU)
Portland, OR